摘要
目的探讨西妥昔单抗联合SOX方案治疗大肠癌的效果及其对血清miR-29b与miR-92a-1水平的影响。方法选择大连大学附属新华医院肛肠科2016年3月至2018年3月收治的84例大肠癌患者,随机分为SOX组和联合组,每组42例。SOX组采取SOX方案化疗,21 d为1个周期,共8个周期。联合组在SOX方案基础上联合西妥昔单抗,每2周1次。比较两组有效率、疾病控制率、化疗前后的血清miR-29b与miR-92a-1表达水平、不良反应、无进展生存期与总生存期。结果两组有效率接近,差异无统计学意义(P>0.05),联合组疾病控制率为85.71%,高于SOX组的66.67%(P<0.05)。化疗后,两组血清miR-29b和miR-92a-1表达水平均较化疗前降低(P<0.05)。联合组化疗后的血清miR-29b和miR-92a-1表达水平均低于SOX组(P<0.05)。两组不良反应发生率的差异无统计学意义(P>0.05)。截至2019年4月,两组随访时间比较差异无统计学意义(P>0.05)。联合组无进展生存期与总生存期长于SOX组,差异有统计学意义(P<0.05)。结论西妥昔单抗联合SOX方案治疗大肠癌可提高疾病控制率,延长生存时间,并下调患者血清miR-29b和miR-92a-1表达,且不会增加不良反应,患者耐受性较好。
Objective To investigate the effect of Cetuximab combined with SOX regimen in the treatment of colorectal cancer and its effect on serum levels of miR-29b and miR-92a-1.Methods A total of 84 patients with colorectal cancer admitted to the Department of Proctology from Mar.2016 to Mar.2018 were randomly divided into SOX group and combined group,42 cases in each group.The SOX group received chemotherapy with SOX regimen for 21 days of 1 cycle,a total of 8 cycles.The combined group combined Cetuximab with the SOX regimen once every 2 weeks.The effective rate,disease control rate,serum levels of miR-29b and miR-92a-1,adverse reactions,progression-free survival and overall survival were compared between the two groups.Results The effective rate of the two groups was close(P>0.05),and the disease control rate of the combined group was 85.71%,which was higher than that of the SOX group(66.67%,P<0.05).After chemotherapy,the levels of serum miR-29b and miR-92a-1 in the two groups were lower than those before chemotherapy(P<0.05).The serum levels of miR-29b and miR-92a-1 in the combined group were lower than those in the SOX group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).As of Apr.2019,there was no significant difference in the follow-up time between the two groups(P>0.05).The progression-free survival and overall survival of the combined group were longer than those of the SOX group(P<0.05).Conclusion Cetuximab combined with SOX regimen for colorectal cancer can improve disease control rate,prolong survival time,and down-regulate serum levels of miR-29b and miR-92a-1,without significantly increasing adverse reactions,and patients are well tolerated.
作者
于登峰
张文俊
张福杰
程卫东
孙哲
YU Dengfeng;ZHANG Wenjun;ZHANG Fujie;CHENG Weidong;SUN Zhe(Department of Proctology,Dalian University Affiliated Xinhua Hospital,Dalian 116021,China)
出处
《胃肠病学和肝病学杂志》
CAS
2020年第1期53-57,共5页
Chinese Journal of Gastroenterology and Hepatology
